Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer